Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia

2009 ◽  
Vol 62 (2) ◽  
pp. 129-134 ◽  
Author(s):  
H. Hjorth-Hansen ◽  
C. Seidel ◽  
J. Lamvik ◽  
M. Börset ◽  
A. Sundan ◽  
...  
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Elevated Serum ◽  
Serum Concentrations ◽  
Myelocytic Leukaemia ◽  
Acute Myelocytic Leukaemia ◽  
Hepatocyte Growth

Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor

1995 ◽  
Vol 268 (2) ◽  
pp. G380-G386 ◽  
Author(s):  
F. Roos ◽  
A. M. Ryan ◽  
S. M. Chamow ◽  
G. L. Bennett ◽  
R. H. Schwall
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Dextran Sulfate ◽  
Plasma Concentrations ◽  
Elevated Serum ◽  
Serum Levels ◽  
Serum Biochemistry ◽  
Scatter Factor ◽  
Liver Growth ◽  
Hepatocyte Growth

Hepatocyte growth factor/scatter factor (HGF/SF) is a potent stimulator of DNA synthesis in a variety of epithelial cells, including hepatocytes, and has been implicated in liver regeneration. We show here that combining dextran sulfate with HGF/SF markedly increases the plasma concentrations of HGF/SF that are achieved during intraperitoneal infusion. Three days of administration of HGF/SF by this mechanism caused a dose-dependent increase in liver wet weight. Mitotic figures were rarely observed in control livers but were abundant in livers exposed to HGF/SF, and liver DNA content was elevated. Serum levels of triglycerides, cholesterol, total protein, and albumin were also dose dependently increased, whereas alkaline phosphatase was reduced. From these data we conclude 1) that combining HGF/SF with dextran sulfate provides a novel method for delivering HGF/SF in a continuous manner, 2) that HGF/SF can induce liver growth in an intact animal, and 3) that HGF/SF-induced liver enlargement is associated with changes in serum biochemistry.

scholarly journals Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple Myeloma

Blood ◽  
1998 ◽  
Vol 91 (3) ◽  
pp. 806-812 ◽  
Author(s):  
Carina Seidel ◽  
Magne Børset ◽  
Ingemar Turesson ◽  
Niels Abildgaard ◽  
Anders Sundan ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Growth Factor ◽  
Prognostic Factor ◽  
Hepatocyte Growth Factor ◽  
Cox Regression ◽  
Elevated Serum ◽  
Cox Regression Analysis ◽  
Β2 Microglobulin ◽  
Serial Samples ◽  
Hepatocyte Growth

Abstract Serum from 398 myeloma patients at diagnosis and serial samples from 29 patients were analysed for hepatocyte growth factor (HGF). HGF was elevated at diagnosis in 43% of myeloma patients compared with healthy controls (median 1.00 ng/mL and 0.44 ng/mL, respectively;P < .00001). In the group with elevated HGF levels 46% of the patients reached plateau phase, as compared with 60% of the patients with low HGF levels (P = .005), and the median survival time was 21 and 32 months, respectively (P = .002). In a univariate Cox regression analysis, HGF was a significant predictor of mortality (P = .02). In the subgroup of patients with β2-microglobulin levels less than or equal to 6 mg/L, high versus low HGF was a prognostic factor when a multivariate Cox regression analysis was performed. In serial samples HGF was higher at the time of diagnosis and relapse (median 0.57 ng/mL and 0.52 ng/mL, respectively; P = .0018) than at response (median 0.24 ng/mL, P = .008). We conclude that HGF may be a useful follow-up parameter in myeloma patients. Measurement of HGF may identify a group of patients with poor response to melphalan-prednisone treatment and short survival. HGF was a prognostic factor in patients with high levels of β2-microglobulin.

scholarly journals Elevated serum level of hepatocyte growth factor predicts development of new syndesmophytes in men with ankylosing spondylitis

Rheumatology ◽  
2020 ◽  
Author(s):  
Anna Deminger ◽  
Eva Klingberg ◽  
Merja Nurkkala ◽  
Mats Geijer ◽  
Hans Carlsten ◽  
...  
Keyword(s):  
Cohort Study ◽  
Ankylosing Spondylitis ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Radiographic Progression ◽  
Elevated Serum ◽  
Regression Analyses ◽  
Baseline Serum ◽  
Hepatocyte Growth

Abstract Objectives To study baseline serum hepatocyte growth factor (s-HGF) as a predictor of spinal radiographic progression overall and by sex and to analyse factors correlated to changes in s-HGF in patients with AS. Methods At baseline and the 5-year follow-up, s-HGF was analysed with ELISA. Spinal radiographs were graded according to modified Stoke Ankylosing Spondylitis Spinal Score. Radiographic progression was defined as ≥2 modified Stoke Ankylosing Spondylitis Spinal Score units/5 years or development of ≥1 syndesmophyte. Logistic regression analyses were used. Results Of 204 baseline participants, 163 (80%) completed all examinations at the 5-year follow-up (54% men). Baseline s-HGF was significantly higher in men who developed ≥1 syndesmophyte compared with non-progressors, median (interquartile range) baseline s-HGF 1551 (1449–1898) vs 1436 (1200–1569) pg/ml, P = 0.003. The calculated optimal cut-off point for baseline s-HGF ≥1520 pg/ml showed a sensitivity of 70%, a specificity of 69% and univariate odds radio (95% CI) of 5.25 (1.69, 14.10) as predictor of development of ≥1 new syndesmophyte in men. Baseline s-HGF ≥1520 pg/ml remained significantly associated with development of ≥1 new syndesmophyte in men in an analysis adjusted for the baseline variables age, smoking, presence of syndesmophytes and CRP, odds radio 3.97 (1.36, 11.60). In women, no association with HGF and radiographic progression was found. Changes in s-HGF were positively correlated with changes in ESR and CRP. Conclusion In this prospective cohort study elevated s-HGF was shown to be associated with development of new syndesmophytes in men with AS.

scholarly journals Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple Myeloma

Blood ◽  
1998 ◽  
Vol 91 (3) ◽  
pp. 806-812 ◽  
Author(s):  
Carina Seidel ◽  
Magne Børset ◽  
Ingemar Turesson ◽  
Niels Abildgaard ◽  
Anders Sundan ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Growth Factor ◽  
Prognostic Factor ◽  
Hepatocyte Growth Factor ◽  
Cox Regression ◽  
Elevated Serum ◽  
Cox Regression Analysis ◽  
Β2 Microglobulin ◽  
Serial Samples ◽  
Hepatocyte Growth

Serum from 398 myeloma patients at diagnosis and serial samples from 29 patients were analysed for hepatocyte growth factor (HGF). HGF was elevated at diagnosis in 43% of myeloma patients compared with healthy controls (median 1.00 ng/mL and 0.44 ng/mL, respectively;P < .00001). In the group with elevated HGF levels 46% of the patients reached plateau phase, as compared with 60% of the patients with low HGF levels (P = .005), and the median survival time was 21 and 32 months, respectively (P = .002). In a univariate Cox regression analysis, HGF was a significant predictor of mortality (P = .02). In the subgroup of patients with β2-microglobulin levels less than or equal to 6 mg/L, high versus low HGF was a prognostic factor when a multivariate Cox regression analysis was performed. In serial samples HGF was higher at the time of diagnosis and relapse (median 0.57 ng/mL and 0.52 ng/mL, respectively; P = .0018) than at response (median 0.24 ng/mL, P = .008). We conclude that HGF may be a useful follow-up parameter in myeloma patients. Measurement of HGF may identify a group of patients with poor response to melphalan-prednisone treatment and short survival. HGF was a prognostic factor in patients with high levels of β2-microglobulin.

scholarly journals Analysis of Soluble Mesenchymal-Epithelial Transition Factor and Hepatocyte Growth Factor Serum Levels in Children With Autism Spectrum Disorder

2022 ◽  
Vol 8 (1) ◽  
pp. 26-32
Author(s):  
Somayeh Shabani ◽  
◽  
Soheila Talesh Sasani ◽  
Farhad Mashayekhi ◽  
◽  
...  
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Serum Levels ◽  
Autism Spectrum ◽  
Vital Role ◽  
Serum Concentrations ◽  
Neurology Clinic ◽  
The Mean ◽  
Mesenchymal Epithelial Transition Factor ◽  
Hepatocyte Growth

Background: Hepatocyte Growth Factor (HGF) and its receptor, Mesothelial-Epithelial Transition (cMet) factor signaling, play an essential role in controlling synaptogenesis. Objectives: Because of the vital role of HGF and Met signaling in synaptogenesis and spatial learning function of the brain’s hippocampal region, we aimed to study the HGF and soluble cMet (s-cMet) serum levels in children with different stages of Autism Spectrum Disorders (ASD). Materials & Methods: A total of 189 ASD patients (mild; n=69, moderate; n=63 and severe; n=57) and 82 control were enrolled in this project. Blood samples were collected from ASD patients referred to Pediatric Neurology Clinic, 17 Shahrivar Hospital, Rasht City, Iran, and serum concentrations of s-cMet and HGF were measured by ELISA. The control children with no clinical characteristics of ASD attended routine blood tests. Results: HGF Mean±SD serum concentration in ASD patients was 239±52.02 pg/mL compared to controls which was 360.04±71.15 pg/mL (P=0.004). Also, the Mean±SD serum concentrations of HGF in mild, moderate, and severe ASD patients were 297.54±69.82, 232.81±56.41, and 189±33.25 ng/mL, respectively, compared to control, which was 360.18±57.40. Besides, the s-cMet Mean±SD serum concentrations in ASD and controls were 143.54±32.50 and 200.25±31.16 pg/mL, respectively (P=0.005). The Mean±SD serum concentrations of s-cMet in the mild, moderate, and severe ASD patients were 172.81±37.69, 129.81±45.55, and 85.18±22.95 ng/mL, respectively, as compared to the control, which was 214.54±34.17 ng/mL. Conclusion: Serum HGF and s-cMet concentration decreased in ASD patients corresponding to disease severity. Also, detecting serum HGF and s-cMet may help classify ASD.

Sign in / Sign up

Export Citation Format

Share Document